Read by QxMD icon Read

Clinical Colorectal Cancer

Emily Cannon, Steven Buechler
BACKGROUND: Cancers of the right colon have been shown to differ from left-side colon cancers in prognosis, response to epithelial growth factor receptor inhibitors, microsatellite instability and BRAF mutation status, and other molecular characteristics. Clinical application of these differences will benefit from a deeper understanding of how tumor location defines and is defined by gene expression. MATERIALS AND METHODS: This study was carried out using Affymetrix microarray datasets (Cohort A: training set, n = 352; validation set, n = 519) and samples from The Cancer Genome Atlas Colon Adenocarcinoma database (Cohort B: n = 408), in which tumor location was reported...
February 14, 2019: Clinical Colorectal Cancer
M Ibrahim Khot, Helen Andrew, Hafdis S Svavarsdottir, Gemma Armstrong, Aaron J Quyn, David G Jayne
Oncologic thermal ablation involves the use of hyperthermic temperatures to damage and treat solid cancers. Thermal ablation is being investigated as a method of treatment in colorectal cancers and has the potential to complement conventional anticancer treatments in managing local recurrence and metastatic disease. Photothermal therapy utilizes photosensitive agents to generate local heat and induce thermal ablation. There is growing interest in developing nanotechnology platforms to deliver such photosensitive agents...
February 14, 2019: Clinical Colorectal Cancer
Lorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, Stefano Cordio, Sara Lonardi, Laura Toppo, Alberto Zaniboni, Roberto Bordonaro, Maria Di Bartolomeo, Gianluca Tomasello, Vincenzo Dadduzio, Maria Chiara Tronconi, Chiara Piombo, Laura Giordano, Annunziata Gloghini, Luca Di Tommaso, Armando Santoro
BACKGROUND: MET overexpression/amplification has been associated with resistance to anti- epidermal growth factor receptor therapies in patients with metastatic colorectal cancer (mCRC). Combining tivantinib, an inhibitor of the MET receptor tyrosine kinase, and cetuximab may be effective in patients with epidermal growth factor receptor-resistant MET-high mCRC. PATIENTS AND METHODS: This multicenter, single-arm, Simon 2-stage, phase II study enrolled patients with MET-high, KRAS wild-type mCRC, who were treated with ≥ 1 prior systemic therapy, with at least stable disease on the last treatment regimen containing cetuximab or panitumumab...
February 14, 2019: Clinical Colorectal Cancer
Alfred I Neugut, Aijing Lin, Gabriel T Raab, Grace Clarke Hillyer, Deborah Keller, Daniel S O'Neil, Melissa Kate Accordino, Ravi P Kiran, Jason Wright, Dawn L Hershman
BACKGROUND: Shortly after the year 2000, randomized trials demonstrated that patients with metastatic colon cancer treated with infusional 5-fluorouracil (5-FU)/leucovorin with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) had a comparable progression-free survival benefit, superior to patients who received 5-FU/leucovorin alone. Factors associated with the initial receipt of the FOLFOX or FOLFIRI regimen are unknown. Our goal was to investigate the patterns and predictors of use for first-line FOLFOX and FOLFIRI...
January 31, 2019: Clinical Colorectal Cancer
Salman Yousuf Guraya
Surgery remains the mainstay of curative treatment for colorectal cancer (CRC). Despite curative surgery, some patients experience cancer recurrence. However, the pattern, stage, and time of recurrent disease (RD) remain unknown. We aimed to determine the pattern and stage of RD after curative open and laparoscopic surgery for CRC. Databases were searched using selected keywords for clinical studies that analyzed the pattern, stage, and time of RD from CRC. A systematic protocol was used for data extraction, data synthesis, and interpretation of results...
January 29, 2019: Clinical Colorectal Cancer
Johannes J M Kwakman, Erik van Werkhoven, Lieke H J Simkens, Johan M van Rooijen, Yes A J van de Wouw, Albert J Ten Tije, Geert-Jan M Creemers, Mathijs P Hendriks, Maartje Los, Robbert J van Alphen, Marco B Polée, Erik W Muller, Ankie M T van der Velden, Theo van Voorthuizen, Miriam Koopman, Linda Mol, Cornelis J A Punt
No abstract text is available yet for this article.
January 29, 2019: Clinical Colorectal Cancer
Maxime J M van der Valk, Floris A Vuijk, Hein Putter, Cornelis J H van de Velde, Geerard L Beets, Denise E Hilling
BACKGROUND: The neoadjuvant rectal score (NAR) was developed as a surrogate endpoint for overall survival in patients with rectal cancer after neoadjuvant treatment. We aimed to validate the NAR score in patients from the Netherlands Cancer Registry database. PATIENTS AND METHODS: We studied patients with rectal cancer treated with long-course neoadjuvant therapy followed by surgery in the Netherlands between 2007 and 2014. The probability of concordance with overall survival and the goodness of fit of several models were evaluated using Harrell's concordance index (c index) and the Akaike information criterion (AIC), which is used to compare the quality of statistical models...
January 19, 2019: Clinical Colorectal Cancer
Gonzalo Tapia Rico, Timothy Price, Niall Tebbutt, Jennifer Hardingham, Chee Lee, Luke Buizen, Kate Wilson, Val Gebski, Amanda Townsend
BACKGROUND: For metastatic colorectal cancer, previous reports have described differences in biology and outcome, including response to biologic agents, based on whether the primary tumor is right- or left-sided. We explored the molecular markers from the AGITG MAX trial. PATIENTS AND METHODS: The AGITG MAX trial was a randomized study comparing capecitabine versus capecitabine + bevacizumab versus capecitabine + bevacizumab + mitomycin C as first-line therapy in advanced colorectal cancer...
January 3, 2019: Clinical Colorectal Cancer
Omar Abdel-Rahman
PURPOSE: To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens. PATIENTS AND METHODS: A pooled analysis of data sets from 5 clinical trials (NCT00115765, NCT00364013, NCT00272051, NCT00305188, NCT00384176) was performed. Kaplan-Meier analysis and log-rank testing were used to assess the differences in overall and progression-free survival between male and female subjects...
December 28, 2018: Clinical Colorectal Cancer
Fatma Sena Dost Gunay, Bilge Ayca Kırmızı, Arzu Ensari, Fikri İcli, Hakan Akbulut
BACKGROUND: In the present study, we investigated the prognostic and predictive role of neuroendocrine differentiation (NED) and tumor-associated macrophage (TAM) infiltration in tumor tissue from patients with advanced colorectal cancer who had received bevacizumab plus chemotherapy. PATIENTS AND METHODS: A total of 123 consecutive patients with advanced colorectal cancer who had received bevacizumab plus irinotecan/oxaliplatin-based combination chemotherapy were included in the present study...
December 27, 2018: Clinical Colorectal Cancer
Rachel Carroll, Shanshan Zhao
BACKGROUND: Colorectal cancer (CRC) is common worldwide, with 140,250 diagnoses and 50,630 deaths estimated for the United States in 2018. Guidelines current to the most recent individuals in our analysis suggested regular screenings beginning at age 50 have reduced the incidence of CRC. However, the incidence continues to rise among those under 50. Less is known about survival following CRC diagnosis, but research has suggested that younger cases may also have worse survival. However, we hypothesize that younger individuals are generally healthier with fewer comorbidities, leading to the potential for better survival following diagnosis...
December 22, 2018: Clinical Colorectal Cancer
Nunzio Digiacomo, Elena Bolzacchini, Giovanni Veronesi, Roberta Cerutti, Nora Sahnane, Graziella Pinotti, Marco Bregni, Salvatore Artale, Claudio Verusio, Filippo Crivelli, Carlo Capella, Fausto Sessa, Daniela Furlan
BACKGROUND: Approximately 10% of metastatic colorectal cancer (mCRC) cases will harbor the BRAF p.V600E mutation (BRAF-mCRC) and have been associated with a poor prognosis. Although they are usually considered a unique clinical entity, biologic heterogeneity has been described. We performed an extensive clinicopathologic study of a multicenter series of BRAF-mCRC to highlight differences between tumors with microsatellite instability (MSI) and microsatellite stable tumors, focusing on both inflammatory profiles and neuroendocrine differentiation...
December 20, 2018: Clinical Colorectal Cancer
Laura M Legué, Geert-Jan Creemers, Ignace H J T de Hingh, Valery E P P Lemmens, Clément J Huysentruyt
Until recently, many classifications existed for the terminology and histopathologic classification of appendiceal mucinous neoplasms, mucinous appendiceal adenocarcinomas, and pseudomyxoma peritonei (PMP). A major accomplishment was achieved by consensus-based histopathologic classifications on behalf of the Peritoneal Surface Oncology Group International regarding mucinous appendiceal tumours and PMP. As different classifications were used over the years and also owing to the rare nature of these tumors, many clinicians are not familiar with the terminology and the impact on patient management...
December 6, 2018: Clinical Colorectal Cancer
Jeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, Kristy P Robledo, Christos S Karapetis, Fiona L Day, Louise M Nott, Michael Jefford, Lorraine A Chantrill, Nick Pavlakis, Niall C Tebbutt, Timothy J Price, Mustafa Khasraw, Guy A Van Hazel, Paul M Waring, Sabine Tejpar, John Simes, Val J Gebski, Jayesh Desai, Eva Segelov
BACKGROUND: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS: Patients were enrolled in an open-label, multicenter, phase II trial and randomly assigned to cetuximab 400 mg/m2 , then 250 mg/m2 cetuximab weekly, with or without irinotecan 180 mg/m2 every 2 weeks...
December 2018: Clinical Colorectal Cancer
Bin Ma, Peng Gao, Yongxi Song, Xuanzhang Huang, Hongchi Wang, Qingzhou Xu, Shan Zhao, Zhenning Wang
BACKGROUND: To assess whether preoperative short-course radiotherapy (PSRT) could be the treatment of choice compared to preoperative long-course chemoradiotherapy (PLCRT) METHODS: The PubMed, Embase, and Web of Science Databases were searched to conduct a systematic review and meta-analysis. Perioperative and survival outcomes between PSRT and PLCRT were selected as end points for our meta-analysis. In addition, health-related quality-of-life outcomes were also systematically reviewed between PSRT and PLCRT...
December 2018: Clinical Colorectal Cancer
Yu Sunakawa, Dongyun Yang, Shu Cao, Wu Zhang, Miriana Moran, Stephanie H Astrow, Jack Hsiang, Craig Stephens, Akihito Tsuji, Takehiro Takahashi, Hiroaki Tanioka, Yuji Negoro, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Tetsuya Eto, Masashi Fujii, Wataru Ichikawa, Heinz-Josef Lenz
BACKGROUND: Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-related genes affect the NLR remain unclear. PATIENTS AND METHODS: In 77 patients with KRAS exon2 wild-type mCRC from prospective trials of first-line chemotherapy with cetuximab, expression levels of 354 immune-related genes were measured in tissue samples obtained from all patients by the HTG EdgeSeq Oncology Biomarker Panel...
December 2018: Clinical Colorectal Cancer
Sumana Narayanan, Emmanuel Gabriel, Kristopher Attwood, Patrick Boland, Steven Nurkin
BACKGROUND: Previous studies have shown that variability in molecular markers correlates with poorer survival outcomes in patients with right-sided colon cancer (RCC) compared with left-sided colon cancer (LCC). However, several studies have shown conflicting results when examined stage for stage. We examined RCC and LCC to assess for differences in histopathologic features and overall survival (OS). MATERIALS AND METHODS: The National Cancer Database was used to identify patients with RCC and LCC from 2004 to 2013...
December 2018: Clinical Colorectal Cancer
James J Lee, Edward Chu
Metastatic colorectal cancer (mCRC) continues to be associated with a poor prognosis, and there remains a significant unmet need for novel agents and treatment regimens. Major breakthroughs have been made with immune checkpoint blockade therapy in several disease types, including DNA mismatch repair deficient/microsatellite instability-high (MSI-H) tumors. To date, however, immune checkpoint monotherapy has not shown significant clinical activity in the treatment of patients with mismatch repair proficient (pMMR)/non-MSI-H mCRC...
December 2018: Clinical Colorectal Cancer
Amandine Gouverneur, Juliette Coutureau, Jérémy Jové, Magali Rouyer, Angela Grelaud, Sophie Duc, Stéphane Gérard, Denis Smith, Alain Ravaud, Cécile Droz, Marie-Agnès Bernard, Régis Lassalle, Annie Forrier-Réglat, Pernelle Noize
BACKGROUND: Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. PATIENTS AND METHODS: Two field cohorts of patients initiating bevacizumab or cetuximab for first-line mCRC were pooled. Patients characteristics, use, and safety were compared between younger and elderly patients (<75 vs...
November 29, 2018: Clinical Colorectal Cancer
J Connor Wells, Dongsheng Tu, Lillian L Siu, Jeremy D Shapiro, Derek J Jonker, Christopher S Karapetis, John Simes, Geoffrey Liu, Timothy J Price, Niall C Tebbutt, Chris J O'Callaghan
BACKGROUND: The safety and efficacy of targeted therapy in older patients (≥ 70 years) with metastatic colorectal cancer is not well evaluated. PATIENTS AND METHODS: Outcomes of older patients (including overall survival [OS], progression-free survival [PFS], toxicity, and quality of life [QoL]) were compared to young patients using data from 2 large previously reported clinical trials, CO.17 (cetuximab vs. best supportive care) and CO.20 (cetuximab plus placebo vs...
November 28, 2018: Clinical Colorectal Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"